Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Xi Guo

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-3152-0282; OpenAlex author ID A5027049354. Sources: OpenAlex.

Their work

Papers
6 (first author 2, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
28
Papers, trials and grants by year

2018: 1 paper · 2019: 1 paper · 2020: none · 2021: none · 2022: 1 paper · 2023: 1 paper · 2024: 2 papers

Papers 6

  1. Identification of Novel Tumor Pyroptosis-Related Antigens and Pyroptosis Subtypes for Developing mRNA Vaccines in Pancreatic Adenocarcinoma. Last author DOI 10.3390/biomedicines12040726↗
  2. Efficacy of nab‑paclitaxel vs. Gemcitabine in combination with S‑1 for advanced pancreatic cancer: A multicenter phase II randomized trial. Co-author DOI 10.3892/ol.2024.14293↗
  3. Additional adjuvant radiotherapy improves survival at 1 year after surgical treatment for pancreatic cancer patients with T4, N2 disease, positive resection ma… Co-author DOI 10.3389/fonc.2023.1109068↗
  4. Early Assessment of Chemoradiotherapy Response for Locally Advanced Pancreatic Ductal Adenocarcinoma by Dynamic Contrast-Enhanced Ultrasound. First author DOI 10.3390/diagnostics12112662↗
  5. Consolidative Chemoradiotherapy After Induced Chemotherapy Is an Optimal Regimen for Locally Advanced Pancreatic Cancer. Co-author DOI 10.3389/fonc.2019.01543↗
  6. Efficacy and safety comparison of nabpaclitaxel plus S-1 and gemcitabine plus S-1 as first-line chemotherapy for metastatic pancreatic cancer. First author DOI 10.1093/jjco/hyy063↗

Closest collaborators

The 25 strongest of 28 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yuhong Zhou · 4 shared papers, 2018–2024 · strength 0.56
  2. Lili Wu · 4 shared papers, 2018–2024 · strength 0.48
  3. Yaolin Xu · 3 shared papers, 2018–2024 · strength 0.40
  4. Dansong Wang · 3 shared papers, 2018–2024 · strength 0.40
  5. Wenchuan Wu · 3 shared papers, 2018–2024 · strength 0.40
  6. Yefei Rong · 2 shared papers, 2024 · strength 0.38
  7. Yue Fan · 3 shared papers, 2018–2023 · strength 0.33
  8. Wenhui Lou · 2 shared papers, 2023–2024 · strength 0.32
  9. Yuhong Zhou · 2 shared papers, 2022–2024 · strength 0.31
  10. Yuan Ji · 2 shared papers, 2019–2024 · strength 0.24
  11. Qiaowei Lin · 1 shared paper, 2024 · strength 0.23
  12. Lie Yao · 1 shared paper, 2024 · strength 0.16
  13. Xuefeng Xu · 1 shared paper, 2024 · strength 0.16
  14. Wenquan Wang · 1 shared paper, 2024 · strength 0.16
  15. Liang Liu · 1 shared paper, 2024 · strength 0.16
  16. Dayong Jin · 1 shared paper, 2024 · strength 0.16
  17. Tiantao Kuang · 1 shared paper, 2024 · strength 0.16
  18. Jing Liu · 1 shared paper, 2024 · strength 0.16
  19. Jun Zhang · 1 shared paper, 2024 · strength 0.16
  20. Deliang Fu · 1 shared paper, 2024 · strength 0.16
  21. Xiaowei Liu · 1 shared paper, 2024 · strength 0.16
  22. Dan Zuo · 1 shared paper, 2022 · strength 0.15
  23. Qi Zhang · 1 shared paper, 2022 · strength 0.15
  24. Xiu-Yun Lu · 1 shared paper, 2022 · strength 0.15
  25. Wen‐Ping Wang · 1 shared paper, 2022 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.